Monitor for actual execution of the planned sale; while 10b5-1 plans reduce short-term signaling risk, sustained insider selling could indicate waning confidence, especially in a high-growth biotech with no current revenue.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $85.40entry
- T+1 · 8mo ago −0.15%α −0.63% · $85.27
- T+5 · 7mo ago −0.41%α −4.03% · $85.05
- T+20 · 7mo ago −5.07%α −14.95% · $81.07
- T+60 · 5mo ago +34.27%α +20.11% · $114.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Elena Ridloff, a director at Kymera Therapeutics, filed a Form 144 to sell up to 4,600 shares, following the exercise of stock options. This sale is part of a pre-arranged 10b5-1 trading plan and follows recent insider selling activity totaling $3.8M in the past 30 days.
Key Facts
- Elena Ridloff, director of Kymera Therapeutics, filed Form 144 to sell up to 4,600 shares.
- The shares were acquired through the exercise of stock options on March 31, 2026, and the sale is planned for April 1, 2026.
- This is part of a pre-arranged 10b5-1 plan, indicating non-discretionary timing.
- Ridloff has already sold 7,400 shares on March 31, 2026, for approximately $631,739.
- Recent insider activity includes four sell transactions totaling $3.8M in the past 30 days.
Financial Impact
Approximately $383,134 based on 4,600 shares at ~$83.30 per share (implied from prior sale)
Risk Factors
- Increased insider selling pressure if other directors or executives follow suit.
- Potential negative market perception if multiple 10b5-1 sales cluster around earnings or clinical trial readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003152 |
| Document: 0001950047-26-003152-index.html | 0001950047-26-003152 |
| Document: 0001950047-26-003152.txt | 0001950047-26-003152 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers